Trial Profile
A comparative study on efficacy of Deferasirox (Exjade) versus Osveral in treatment of iron overload in patients with beta thalassemia major
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 18 Jun 2018
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Beta-thalassaemia
- Focus Therapeutic Use
- 18 Jun 2018 New trial record